Targeted Drugs can Cure Cancer; Clay Siegall Rigorous Research Conviction

Clay Siegall graduated from the University of Maryland with a Bachelor of Science in Zoology and later attained his Ph.D. in Genetics from George Washington University. He started working at the National Cancer Institute, National Institutes of Health in 1988 before leaving to join Bristol-Myers Squibb Pharmaceutical Research Institute in 1991. He did not stay for long as in 1997 he left the research firm and started his own Seattle Genetics in 1998. His story has been of success and intense research holding 15 patents and over 70 publications.

He serves as the Chairman of the board of directors, CEO, and president of Seattle Genetics. Under his guidance, the firm has been able to develop different kinds of antibody-based cancer therapies. The famous one is the FDA approved ADCETRIS (brentuximab vedotin). Additionally, he has led the company in raising capital through a successful IPO in 2001 and other private and public funding initiatives.

Being a trained scientist, Clay Siegall employed demanding research, drug development strategies, and scientific advancement to found Seattle Genetics due to his compassion for helping patients. The company develops antibody-drug conjugates (ADCs) such as ADCETRIS (brentuximab vedotin) which was in collaboration with Takeda Pharmaceuticals. ADCETRICS have developed into a worldwide brand with approval in more than 65 countries. The company is accelerating its development of diverse proprietary ADCs products mostly for cancer treatment. There are over 20 ADCs that are undergoing clinical trial and development between Seattle Genetics, internal and collaborator programs.

The quest for ADCs technology has been tremendous, leading Clay Siegall and Seattle Genetics to enter in numerous strategic partnerships with leading global pharmaceutical giants such as Pfizer, Genentech (Roche), GlaxoSmithKline and AbbVie, among others. Clay Siegall is a board of director’s member of Alder Biopharmaceuticals, Ultragenyx Pharmaceuticals, and Washington Roundtable.

After seeing some of his employee’s patents get high rewarding returns at Bristol-Myers, he decided to dedicate his life to research. This was also influenced by the painful and limited treatment methods and tools for oncologists in treating cancer such as chemotherapy and radiation. He has sought to come up with a better treatment method like targeted drugs, and his relentless efforts shave started paying off, both in his purpose to help cancer patients and financially.